Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.11 and traded as high as $5.10. Cumberland Pharmaceuticals shares last traded at $4.77, with a volume of 18,505 shares traded.
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, March 6th.
Read Our Latest Research Report on Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Stock Down 0.8 %
The company has a market capitalization of $67.47 million, a price-to-earnings ratio of -6.27 and a beta of -0.24. The firm's 50-day simple moving average is $4.81 and its 200-day simple moving average is $3.12. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.99 and a current ratio of 1.13.
Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The firm had revenue of $10.44 million during the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP raised its stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 37,649 shares of the specialty pharmaceutical company's stock after acquiring an additional 18,271 shares during the period. Two Sigma Investments LP owned about 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 15.51% of the company's stock.
Cumberland Pharmaceuticals Company Profile
(
Get Free Report)
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
See Also
Before you consider Cumberland Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cumberland Pharmaceuticals wasn't on the list.
While Cumberland Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
